TRIPP PsyAssist

Want to be at the forefront of the emerging convergence between mental health, technology, and consciousness?

TRIPP is excited to launch a new business segment to address the growing spectrum of challenges we are facing around the world with respect to mental health and well-being.

TRIPP PsyAssist will soon be offering innovative, research-based protocols and related content to safely support therapists and patients. Join the TRIPP PsyAssist waitlist and be the first to know when this new service offering becomes available.

Join The Waitlist!

In recent years, psychedelic molecules have moved from being categorized as illegal, Schedule I substances to central components in groundbreaking clinical treatments for mental health conditions like depression, anxiety, addiction, and post-traumatic stress disorder (PTSD).

Yet, even with ongoing clinical trials of psychedelic-assisted therapies and the clinical availability of ketamine to address mental health issues, patients need support with onboarding, pre-session anxiety reduction, and post-session integration, whether in-clinic or at home.

TRIPP PsyAssist will initially provide research based, practitioner designed support for ketamine-assisted therapy and expand from there. Our initial offering will help reduce patient anxiety before treatment and provide integration support post-treatment by combining TRIPP’s VR, AR, and mobile platforms, along with targeted protocols for psychedelic-assisted therapy.

TRIPP PsyAssist Waitlist

  • This field is for validation purposes and should be left unchanged.